This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

News
8 Oct 2011

Merck & Ono Pharmaceutical Sign Collaboration Agreements

The first agreement grants Merck worldwide exclusive license rights for the development and commercialization of ONO-4641 outside of Japan, Korea and Taiwan. The second license agreement provides Ono with co-development and co-marketing rights of Stimuvax in Japan.

Merck KGaA announced that it signed two agreements for collaboration of its Merck Serono division with Ono Pharmaceutical Co., Ltd., Osaka, Japan to strengthen its multiple sclerosis and cancer franchises.

 

The first agreement grants Merck worldwide exclusive license rights for the development and commercialization of ONO-4641 outside of Japan, Korea and Taiwan.

 

ONO-4641 is a novel oral compound currently in Phase II of development that was originally discovered and developed by Ono for the potential treatment of multiple sclerosis.

 

Under the terms of the agreement for ONO-4641, Ono will receive 1.5 billion Japanese Yen (about € 14 million) as an upfront payment and could rece

Related News